Skip to main content

Table 2 Subgroup analyses for MACE

From: Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis

Subgroups HR (95% CI) P value P value for interaction
Age
  < 60–65 years 0.92 (0.77, 1.10) 0.38 0.58
  ≥ 60–65 years 0.85 (0.79, 0.93) 0.001  
Gender
 Male 0.91 (0.85, 0.98) 0.02 0.53
 Female 0.87 (0.78, 0.98) 0.02  
Race
 White 0.94 (0.88, 1.01) 0.09 0.12
 Black 0.77 (0.59, 1.00) 0.05  
 Asian 0.78 (0.62, 0.97) 0.03  
Body mass index
  < 30 kg/m2 0.93 (0.83, 1.05) 0.22 0.69
  ≥ 30 kg/m2 0.88 (0.81, 0.96) 0.008  
Glycated hemoglobin level
  < 8.0–8.5% 0.91 (0.83, 1.00) 0.04 0.73
  ≥ 8.0–8.5% 0.89 (0.82, 0.97) 0.01  
Insulin therapy
 Yes 0.88 (0.81, 0.97) 0.01 0.98
 No 0.88 (0.80, 0.98) 0.01  
Duration of diabetes
  < 10–15 years 0.91 (0.81, 1.02) 0.09 0.74
  ≥ 10–15 years 0.89 (0.82, 0.96) < 0.01  
History of congestive heart failure
 Yes 0.96 (0.85, 1.08) 0.47 0.27
 No 0.87 (0.77, 1.00) 0.05  
Estimated GFR
  ≥ 60 mL/min/1.73m2 0.91 (0.79, 1.05) 0.19 0.82
  < 60 mL/min/1.73m2 0.89 (0.72, 1.09) 0.25  
  ≥ 30 mL/min/1.73m2 0.88 (0.82, 0.95) < 0.001 0.81
  < 30 mL/min/1.73m2 0.87 (0.55, 1.39) 0.57  
  1. CI confidence interval, GFR glomerular filtration rate, HR hazard ratio, MACE major adverse cardiovascular event